渤健公司今日(周三)盘中大跌6.54%,引发市场广泛关注。导致公司股价大跌的主要原因是该公司公布了疲软的2025年利润预期,低于华尔街分析师预期。
据消息,渤健公司预计2025年在剔除汇率影响后,收入将比2024年水平下降中等个位数百分比。公司指导2025年每股收益在15.25美元至16.25美元之间,低于分析师预期的16.34美元。
导致利润预期下滑的主要原因包括:美元走强、阿尔茨海默病新药Leqembi销售增长放缓、多发性硬化症治疗药物面临激烈竞争导致销量下滑,以及成本持续上升等。虽然渤健公司去年聘请了前赛诺菲CEO担任首席执行官,并启动10亿美元成本削减计划、收购Reata制药公司等措施,但似乎难以完全抵消上述不利影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.